Last update March 9, 2021

إيتوريكوكسيب

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Non-steroidal anti-inflammatory drug (NSAID), that functions as a selective inhibitor of the cyclooxygenase-2 (COX-2) enzyme.
Prescribed for the treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis.
Daily oral administration in one dose.

We did not find published data regarding the excretion of this substance through breast milk at the time this last update was completed.

Pharmacokinetic data (large volume of distribution and high percentage of protein binding (CINFA 2020, MSD 2017) make it very unlikely for significant quantities to pass into breastmilk.

Until more published data regarding the interactions of this drug and breastfeeding are made available, the use of an alternative drug with a safer pharmacokinetic profile for lactation would be preferable, especially during the neonatal period or with premature infants.

Alternatives

  • Celecoxib ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Ibuprofen ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

إيتوريكوكسيب is Etoricoxib in Arabic.

Is written in other languages:

Group

إيتوريكوكسيب belongs to this group or family:

Tradenames

Main tradenames from several countries containing إيتوريكوكسيب in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 83 - 100 %
Molecular weight 359 daltons
Protein Binding 92 %
VD 1.7 l/Kg
pKa 19.69 -
Tmax 1 - 2 hours
22 - 25 hours

References

  1. CINFA. Etoricoxib. Ficha técnica. 2020 Full text (in our servers)
  2. MSD. Etoricoxib. Drug Summary. 2017 Full text (in our servers)
  3. Agrawal NG, Porras AG, Matthews CZ, Rose MJ, Woolf EJ, Musser BJ, Dynder AL, Mazina KE, Lasseter KC, Hunt TL, Schwartz JI, McCrea JB, Gottesdiener KM. Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man. J Clin Pharmacol. 2003 Abstract
  4. Rodrigues AD, Halpin RA, Geer LA, Cui D, Woolf EJ, Matthews CZ, Gottesdiener KM, Larson PJ, Lasseter KC, Agrawal NG. Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. Drug Metab Dispos. 2003 Abstract

Total visits

2,441

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM